Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Rebecca, Heltsley"'
Autor:
John W Peabody, Divya Ganesan, Czarlota Valdenor, David Paculdo, Joshua Schrecker, Christopher Westerfield, Rebecca Heltsley
Publikováno v:
BMC Primary Care, Vol 24, Iss 1, Pp 1-10 (2023)
Abstract Background Disentangling nonadherence (NA), drug-drug interactions (DDIs), and disease progression from each other is an important clinical challenge for providers caring for patients with cardiometabolic diseases. NAs and DDIs are both ubiq
Externí odkaz:
https://doaj.org/article/9565fe0cb7844aa89f460d1aade8a527
Autor:
Czarlota Valdenor, Divya Ganesan, David Paculdo, Joshua Schrecker, Rebecca Heltsley, Christopher Westerfield, John W. Peabody
Publikováno v:
International Journal of Clinical Practice. 2022:1-8
Background. Medication nonadherence in patients with chronic diseases is common, costly, and often underdiagnosed. In the United States, approximately 40–50% of patients with cardiometabolic conditions are not adherent to long-term medications. Dru
Autor:
John Peabody, Joshua Schrecker, Rebecca Heltsley, David Paculdo, Enrico de Belen, Diana Tamondong-Lachica, M. Czarina Acelajado, Othman Ouenes, Trina Kennedy, Elaine Jeter
Publikováno v:
Diagnostics, Vol 11, Iss 7, p 1266 (2021)
Drug–drug interactions (DDIs) are a serious problem in the healthcare system, leading to excess healthcare utilization and costs. We conducted a second prospective randomized, controlled trial to further establish the real-world clinical utility of
Externí odkaz:
https://doaj.org/article/fe976fcbc5db40b4bf348af7e989da2d
Publikováno v:
Journal of Addiction Medicine.
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 41:359-369
Fentanyl pharmacokinetic and pharmacodynamic data are limited in mechanically ventilated children. This study aimed to assess the fentanyl pharmacokinetics (PK), the sedation outcome, and the development of tolerance in children receiving fentanyl co
Publikováno v:
Journal of Analytical Toxicology. 42:512-517
Cocaine (COC) is widely abused and associated with significant adverse effects. Forensic and clinical laboratories often test for COC intake through detection of the primary metabolite, benzoylecgonine (BZE) in urine. Testing for BZE alone may result
Autor:
Anne Z, DePriest, Rebecca, Heltsley, David L, Black, John M, Mitchell, Charles, LoDico, Ronald, Flegel, Edward J, Cone
Publikováno v:
Journal of Analytical Toxicology. 40:566-574
Oxymorphone (OM), a prescription opioid and metabolite of oxycodone, was included in the recently published proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. To facilitate toxicological interpretation, this s
Autor:
Edward J. Cone, Ronald Flegel, Rebecca Heltsley, Anne Z. DePriest, Charles LoDico, John M. Mitchell, David L. Black
Publikováno v:
Journal of Analytical Toxicology. 40:575-582
Hydromorphone (HM), a prescription opioid and metabolite of morphine and hydrocodone, has been included in proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This study characterized the time course of HM in h
Autor:
Ron Flegel, John M. Mitchell, Anne Z. DePriest, Rebecca Heltsley, Edward J. Cone, David L. Black, Charles LoDico
Publikováno v:
Journal of Analytical Toxicology. 39:192-202
Oxycodone (OC) is recommended to be included as an analyte tested in the proposed Substance Abuse and Mental Health Services Administration (SAMHSA's) Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OF) Specimens. T
Autor:
David L. Black, Yale H. Caplan, David M. Schwope, Rebecca Heltsley, Edward J. Cone, Anne Z. DePriest
Publikováno v:
Journal of Analytical Toxicology. 38:513-518
Zolpidem (Ambien(®)) is the most prescribed insomnia treatment in the USA; however, little is known about zolpidem metabolite excretion in chronic pain patients. As zolpidem is extensively metabolized in vivo to zolpidem 4-phenyl carboxylic acid (ZC